<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1302244911
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Beyfortus 100 mg per 1 ml
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NIRSEVIMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3781.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Patheon Manufacturing Services LLC " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Patheon Manufacturing Services LLC 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2218]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Sanofi Arabia Trading Co. Ltd
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANOFI WINTHROP INDUSTRIE
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Beyfortus is</p><p>Beyfortus is a medicine given as an injection to protect babies against <em>respiratory syncytial virus </em>(RSV). RSV is a common respiratory virus that usually causes mild symptoms comparable to the common cold. However, especially in babies and older adults, RSV can cause severe illness, including bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) that may lead to hospitalisation or even death. The virus is usually more common during the winter.</p><p>&nbsp;</p><p>Beyfortus contains the active ingredient nirsevimab which is an antibody (a protein designed to attach to a specific target) that attaches to a protein that RSV needs to infect the body. By attaching to this protein, Beyfortus blocks its action, thereby stopping the virus from entering and infecting human cells.</p><p>What Beyfortus is used for</p><p>Beyfortus is a medicine to protect your child from getting RSV disease.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your child should not use Beyfortus if he or she is allergic to nirsevimab or any of the other ingredients of this medicine (listed in section 6).</p><p>Inform your child&rsquo;s doctor, pharmacist or nurse if this applies to your child. If you are not sure<strong>, </strong>check with your child&rsquo;s doctor, pharmacist or nurse before the medicine is given.</p><p><em>If your child shows signs of a severe allergic reaction </em>contact the doctor immediately<em>.</em></p><p><em>&nbsp;</em></p><p>Warnings and precautions</p><p>Tell your doctor or seek medical help immediately if you notice any signs of an <strong>allergic reaction</strong>, such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty breathing or swallowing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the face, lips, tongue or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe itching of the skin, with a red rash or raised bumps</p><p>&nbsp;</p><p>Talk to your healthcare provider before your child is given Beyfortus if they have low numbers of blood platelets (which help blood clotting), a bleeding problem or bruise easily or if they are taking an anticoagulant (a medicine to prevent blood clots).</p><p>&nbsp;</p><p>Children and adolescents</p><p>Do not give this medicine to children between the age of 2 and 18 years of age because it has not been studied in this group.</p><p>&nbsp;</p><p>Other medicines and Beyfortus</p><p>Beyfortus is not known to interact with other medicines. However, tell your doctor, pharmacist or nurse if your child is taking, has recently taken or might take any other medicines.</p><p>&nbsp;</p><p>Beyfortus may be given at the same time as vaccines that are part of the national immunisation program.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Beyfortus is given by a doctor, pharmacist or nurse as a single injection in the muscle. It is usually given in the outer part of the thigh.</p><p>&nbsp;</p><p>The recommended dose is 50 mg for children weighing less than 5 kg and 100 mg for children weighing 5 kg or more.</p><p>&nbsp;</p><p>Beyfortus should be given before the RSV season. The virus is usually more common during the winter (known as the RSV season). If your child is born during the winter, Beyfortus should be given after birth.</p><p>&nbsp;</p><p>If your child is to have a heart operation (cardiac surgery), he or she may be given an extra dose of Beyfortus after the operation to ensure they have adequate protection over the remainder of the RSV season.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effects can include:</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 children)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injection site reaction (i.e. redness, swelling, and pain where the injection is given)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever</p><p>&nbsp;</p><p>Reporting of side effects</p><p>If your child gets any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in the end of this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor, pharmacist or nurse is responsible for storing this medicine and disposing of any unused product correctly. The following information is intended for healthcare professionals.</p><p>&nbsp;</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C - 8&deg;C). After removal from the refrigerator, Beyfortus must be protected from light and used within 8 hours or discarded.</p><p>&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light. Do not freeze, shake or expose to direct heat.</p><p>Any unused medicine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Beyfortus contains</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is nirsevimab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One pre-filled syringe of 0.5 mL solution contains 50 mg nirsevimab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One pre-filled syringe of 1 mL solution contains 100 mg nirsevimab.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are L-histidine, L-histidine hydrochloride, L-arginine hydrochloride, sucrose, polysorbate 80, and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Beyfortus looks like and contents of the pack
Beyfortus is a colourless to yellow solution for injection.

Beyfortus is available as:
•	1 pre-filled syringe packaged with two separate needles of different sizes.
OR
•	1 pre-filled syringe without needles.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sanofi Winthrop Industrie</p><p>82 avenue Raspail</p><p>94250 Gentilly</p><p>France</p><p><strong>Manufacturers </strong></p><p>Patheon Manufacturing Services LLC</p><p>5900 Martin Luther King Jr. Highway</p><p>Greenville, NC 27834</p><p>USA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 15-Novmber-2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ما هو بيفورتس</p><p>بيفورتس هو دواء يُعطى كحقنة لحماية الأطفال من <em>الفيروس المخلوي التنفّسي</em>. هذا الفيروس هو فيروس تنفّسي شائع يسبّب عادة أعراضًا خفيفة مماثلة لنزلات البرد. ومع ذلك، بخاصة عند الأطفال وكبار السنّ، يمكن أن يسبّب الفيروس المخلوي التنفّسي مرضًا شديدًا، بما في ذلك التهاب القصيبات (التهاب الشعب الهوائية الصغيرة في الرئة) والالتهاب الرئوي (التهاب الرئتين) الذي قد يؤدي إلى دخول المستشفى أو حتى الوفاة. عادة ما يكون الفيروس أكثر شيوعًا خلال فصل الشتاء.</p><p>&nbsp;</p><p>يحتوي بيفورتس على المادة الفعالة نيرسيفيماب التي هي جسم مضاد (بروتين مصمّم ليرتبط بهدف معيّن) يرتبط بالبروتين الذي يحتاجه الفيروس المخلوي التنفّسي لإصابة الجسم. من خلال الارتباط بهذا البروتين، يمنع بيفورتس عمله، وبالتالي يمنع الفيروس من دخول الخلايا البشريّة وإصابتها.&nbsp;</p><p>ما هي دواعي استعمال بيفورتس</p><p>بيفورتس هو دواء يحمي طفلك من الإصابة بمرض الفيروس المخلوي التنفّسي. &nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب ألا يستخدم طفلك بيفورتس إذا كان لديه حساسية ضد النيرسيفيماب أو أيّ من مكوّنات هذا الدواء الأخرى (المدرجة في الفقرة رقم 6).</p><p>أخبر طبيب طفلك أو الصيدلي أو الممرّض إذا كان هذا ينطبق على طفلك. إذا لم تكن متأكدًا، استشر طبيب طفلك أو الصيدلي أو الممرّض قبل إعطاء الدواء.</p><p><em>إذا ظهرت على طفلك علامات ردّ فعل تحسسي شديد</em>، اتصل بالطبيب على الفور.</p><p>تحذيرات واحتياطات</p><p>أخبر طبيبك أو اطلب مساعدة طبيّة على الفور إذا لاحظت أيّ علامات لردّ فعل تحسسي، مثل:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفّس أو البلع</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتفاخ الوجه أو الشفتين أو اللسان أو الحلق</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكّة شديدة في الجلد مصحوبة بطفح جلدي أحمر أو نتوءات بارزة</p><p>&nbsp;</p><p dir="RTL">تحدّث إلى مقدّم الرعاية الصحية الخاص بك قبل إعطاء طفلك بيفورتس إذا كان لديه عدد قليل من الصفائح الدمويّة (التي تساعد على تخثّر الدم)، أو مشكلة نزيف أو إذا كان يُصاب بكدمات بسهولة أو إذا كان يتناول مضاد تخثّر (دواء لمنع تجلّط الدم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا تعطِ هذا الدواء للأطفال الذين تتراوح أعمارهم بين سنتين و18 سنة لأنّه لم تتمّ دراسته في هذه المجموعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى و</strong><strong>بيفورتس</strong></p><p dir="RTL">من غير المعروف ما إذا كان بيفورتس يتفاعل مع أدوية أخرى. ولكن، أعلم طبيبك أو الصيدلي أو الممرّض إذا كان طفلك يأخذ أو أخذ مؤخرًا أو قد يأخذ أيّ أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن إعطاء بيفورتس في الوقت ذاته مع اللقاحات التي تشكّل جزءًا من برنامج التحصين الوطني.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُعطي طبيب أو صيدلي أو ممرّض بيفورتس كحقنة واحدة في العضلة. عادة ما يتم حقنه في الجزء الخارجي من الفخذ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها هي 50 مجم للأطفال الذين يقلّ وزنهم عن 5 كجم و 100 مجم للأطفال الذين يبلغ وزنهم 5 كجم أو أكثر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب إعطاء بيفورتس قبل موسم الفيروس المخلوي التنفّسي. عادة ما يكون الفيروس أكثر شيوعًا خلال فصل الشتاء (المعروف بموسم الفيروس المخلوي التنفّسي). إذا ولد طفلك خلال فصل الشتاء، يجب إعطاء بيفورتس بعد الولادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان طفلك سيخضع لعمليّة قلب (جراحة في القلب)، فقد يتم إعطاؤه جرعة إضافيّة من بيفورتس بعد العمليّة للتأكّد من حصوله على حماية كافية خلال الفترة المتبقّية من موسم الفيروس المخلوي التنفّسي.&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أيّ أسئلة أخرى حول استعمال هذا الدواء، اسأل طبيبك أو الصيدلي أو الممرّض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلّها، يمكن أن يسبّب هذا الدواء أعراضًا جانبيّة لا يُصاب بها كلّ المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن تتضمّن الأعراض الجانبيّة ما يلي:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير الشائعة</strong> (قد تُصيب لغاية طفل واحد من كلّ 100 طفل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردّ فعل في موقع الحقن (مثل الاحمرار والتورّم والألم في مكان الحقن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL"><em>&nbsp;</em></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبيّة</strong></p><p dir="RTL">إذا أصيب طفلك بأيّ أعراض جانبيّة، تحدّث إلى الطبيب أو الصيدليّ أو الممرّ ضة. ويتضمّن هذا أيّ أعراض جانبيّة محتملة غير مذكورة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبيّة مباشرةً عبر المذكور في نهاية النشرة. بالإبلاغ عن الأعراض الجانبيّة، يمكنك المساعدة في تقديم المزيد من المعلومات حول سلامة هذا الدواء.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إنّ طبيبك أو الصيدلي أو الممرّض مسؤول عن تخزين هذا الدواء والتخلّص من أيّ منتج غير مستعمل بشكل صحيح. المعلومات التالية مخصصة لمتخصصي الرعاية الصحيّة.</p><p>&nbsp;</p><p dir="RTL">إحفظ هذا الدواء بعيدًا عن نظر الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على علبة الكرتون بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في الثلاجة (بين درجتين مئويّتين و8 درجات مئويّة). بعد إخراج بيفورتس من الثلاجة، يجب حمايته من النور واستعماله في غضون 8 ساعات أو التخلّص منه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالمحقنة المسبقة التعبئة في علبة الكرتون الخارجيّة لحمايتها من النور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمّد الدواء أو ترجّه أو تعرّضه للحرارة المباشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب التخلّص من أي دواء غير مستعمل أو فضلات وفقًا للمتطلّبات المحليّة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي بيفورتس</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي نيرسيفيماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي محقنة واحدة مسبقة التعبئة سعة 0.5 مل من المحلول على 50 مجم من نيرسيفيماب.&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوي محقنة واحدة مسبقة التعبئة سعة 1 مل من المحلول على 100 مجم من نيرسيفيماب.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكوّنات الأخرى هي ل-هيستيدين، هيدروكلوريد ل-هيستيدين، هيدروكلوريد ل-أرجينين، سكروز، بولي سوربات 80، وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>كيف هو شكل بيفورتس ومحتويات العبوة</p><p>بيفورتس هو محلول للحقن عديم اللون إلى أصفر.</p><p>&nbsp;</p><p>يأتي بيفورتس على شكل:</p><p>&middot;&nbsp;&nbsp;&nbsp; محقنة واحدة مسبقة التعبئة موضّبة مع إبرتين منفصلتين بأحجام مختلفة.</p><p>أو</p><p>&middot;&nbsp;&nbsp;&nbsp; محقنة واحدة مسبقة التعبئة بدون إبرة</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">قد لا تكون أحجام العبوات كلّها مسوّقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل رخصة التسويق</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سانوفي وينثروب انداستري</p><p dir="RTL">82 طريق راسبايل</p><p dir="RTL">94250 جينتيلي &nbsp;</p><p dir="RTL">فرنسا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنعة:</strong></p><p dir="RTL">باثيون مانيوفاكشرنج سيرفس ال ال سي</p><p dir="RTL">5900 طريق مارتين لوثر كنج جي ار السريع</p><p dir="RTL">جرين فيلي، إن سي 27834</p><p dir="RTL">الولايات المتحدة الأمريكية</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لهذه النشرة بتاريخ 15- نوفمبر -2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Beyfortus 50 mg solution for injection in pre-filled syringe
Beyfortus 100 mg solution for injection in pre-filled syringe
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Beyfortus 50 mg solution for injection in pre-filled syringe

Each pre-filled syringe contains 50 mg of nirsevimab in 0.5 mL (100 mg/mL). Beyfortus 100 mg solution for injection in pre-filled syringe
Each pre-filled syringe contains 100 mg of nirsevimab in 1 mL (100 mg/mL).

Nirsevimab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear to opalescent, colourless to yellow, pH 6.0 solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.</p><p>Beyfortus should be used in accordance with official recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose is a single dose of 50 mg administered intramuscularly for infants with body weight &lt;5 kg and a single dose of 100 mg administered intramuscularly for infants with body weight</p><p>&ge;5 kg.</p><p>Beyfortus should be administered prior to commencement of the RSV season, or from birth for infants born during the RSV season.</p><p>For infants undergoing cardiac surgery with cardiopulmonary bypass, an additional dose may be administered as soon as the infant is stable after surgery to ensure adequate nirsevimab serum levels. If within 90 days after receiving the first dose of Beyfortus, the additional dose should be 50 mg or 100 mg according to body weight. If more than 90 days have elapsed since the first dose, the additional dose could be a single dose of 50 mg regardless of body weight, to cover the remainder of the RSV season.</p><p>There are no safety and efficacy data available on repeat dosing.</p><p>Dosing in infants with a body weight from 1.0 kg to &lt;1.6 kg is based on extrapolation, no clinical data are available. Exposure in infants &lt;1 kg is anticipated to yield higher exposures than in those weighing more. The benefits and risks of nirsevimab use in infants &lt;1 kg should be carefully considered.</p><p>There are limited data available in extremely preterm infants (Gestational Age [GA] &lt;29 weeks) less than 8 weeks of age. No clinical data available in infants with a postmenstrual age (gestational age at birth plus chronological age) of less than 32 weeks (see section 5.1).</p><p>The safety and efficacy of nirsevimab in children aged 2 to 18 years have not been established. No data are available.</p><p><u>Method of administration</u></p><p>Beyfortus is for intramuscular injection only.</p><p>It is administered intramuscularly, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.</p><p>&nbsp;</p><p><u>Instructions for administration</u></p><p>Beyfortus is available in a 50 mg and a 100 mg pre-filled syringe. Check the labels on the carton and pre-filled syringe to make sure you have selected the correct 50 mg or 100 mg presentation as required.</p><p>Beyfortus 50 mg (50 mg/0.5 mL) pre-filled syringe with a purple plunger rod.</p><p>Beyfortus 100 mg (100 mg/1 mL) pre-filled syringe with a light blue plunger rod.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="docshapegroup3"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:116.9pt;margin-top:-17.05pt;width:153.4pt;height:91pt;z-index:15729152;
 mso-position-horizontal-relative:page' coordorigin="2338,-341" coordsize="3068,1820">
 <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
  o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="docshape4" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;left:2553;top:-342;width:2852;height:1820'>
  <v:imagedata src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
 </v:shape><v:shape id="docshape5" o:spid="_x0000_s1028" style='position:absolute;
  left:2337;top:411;width:682;height:336' coordorigin="2338,412" coordsize="682,336"
  o:spt="100" adj="0,,0" path="m2908,702l2338,426r9,-14l2915,686r-7,16xm2990,709r-67,l2933,695r-18,-9l2938,642r52,67xm2923,709r-15,-7l2915,686r18,9l2923,709xm3019,748r-134,l2908,702r15,7l2990,709r29,39xe"
  fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:formulas/>
  <v:path arrowok="t" o:connecttype="segments"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="205" height="121" src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" />&nbsp; Purple</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group
 id="docshapegroup6" o:spid="_x0000_s1029" style='position:absolute;left:0;
 text-align:left;margin-left:348.7pt;margin-top:-118.35pt;width:161.05pt;
 height:91pt;z-index:15729664;mso-position-horizontal-relative:page'
 coordorigin="6974,-2367" coordsize="3221,1820">
 <v:shape id="docshape7" o:spid="_x0000_s1030" type="#_x0000_t75" style='position:absolute;
  left:7171;top:-2368;width:3024;height:1820'>
  <v:imagedata src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
   o:title=""/>
 </v:shape><v:shape id="docshape8" o:spid="_x0000_s1031" style='position:absolute;
  left:6974;top:-1615;width:677;height:341' coordorigin="6974,-1615"
  coordsize="677,341" o:spt="100" adj="0,,0" path="m7540,-1322r-566,-278l6979,-1615r567,279l7540,-1322xm7625,-1312r-65,l7565,-1327r-19,-9l7570,-1384r55,72xm7560,-1312r-20,-10l7546,-1336r19,9l7560,-1312xm7517,-1274r23,-48l7560,-1312r65,l7651,-1279r-134,5xe"
  fillcolor="black" stroked="f">
  <v:stroke joinstyle="round"/>
  <v:formulas/>
  <v:path arrowok="t" o:connecttype="segments"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="215" height="121" src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" />&nbsp; &nbsp;Light Blue</p><p>Refer to Figure 1 for pre-filled syringe components.</p><p>&nbsp;</p><p><strong>Figure 1: </strong>Luer lock syringe components</p><p>&nbsp;</p><p>&nbsp;</p><p>Finger grip&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rubber stopper&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syringe cap</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image3.png" o:spid="_x0000_i1025" type="#_x0000_t75"
 style='width:263pt;height:76pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
</v:shape><![endif]--><img width="351" height="101" src="file:///C:/Users/e0567920/AppData/Local/Temp/msohtmlclip1/01/clip_image002.jpg" /></p><p>&nbsp;</p><p>Plunger rod</p><p>&nbsp;</p><p>Syringe body</p><p>&nbsp;</p><p>Luer lock</p><p>&nbsp;</p><p><strong>Step 1</strong>: Holding the Luer lock in one hand (avoid holding the plunger rod or syringe body), unscrew the syringe cap by twisting it counter clockwise with the other hand.</p><p>&nbsp;</p><p><strong>Step 2</strong>: Attach a Luer lock needle to the pre-filled syringe by gently twisting the needle clockwise onto the pre-filled syringe until slight resistance is felt.</p><p>&nbsp;</p><p><strong>Step 3</strong>: Hold the syringe body with one hand and carefully pull the needle cover straight off with the other hand. Do not hold the plunger rod while removing the needle cover or the rubber stopper may move. Do not touch the needle or let it touch any surface. Do not recap the needle or detach it from the syringe.</p><p>&nbsp;</p><p><strong>Step 4</strong>: Administer the entire contents of the pre-filled syringe as an intramuscular injection, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Hypersensitivity including anaphylaxis</u></p><p>&nbsp;</p><p>Serious hypersensitivity reactions, including anaphylaxis, have been observed with monoclonal antibodies. If signs and symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, immediately discontinue administration and initiate appropriate medicinal products and/or supportive therapy.</p><p>&nbsp;</p><p><u>Clinically significant bleeding disorders</u></p><p>&nbsp;</p><p>As with any other intramuscular injections, nirsevimab should be given with caution to infants with thrombocytopenia or any coagulation disorder.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed. Monoclonal antibodies do not typically have significant interaction potential, as they do not directly affect cytochrome P450 enzymes and are not substrates of hepatic or renal transporters. Indirect effects on cytochrome P450 enzymes are unlikely as the target of nirsevimab is an exogenous virus.</p><p>&nbsp;</p><p><u>Concomitant administration with vaccines</u></p><p>&nbsp;</p><p>Since nirsevimab is a monoclonal antibody, a passive immunisation specific for RSV, it is not expected to interfere with the active immune response to co-administered vaccines.</p><p>&nbsp;</p><p>There is limited experience of co-administration with vaccines. In clinical trials, when nirsevimab was given with routine childhood vaccines, the safety and reactogenicity profile of the co-administered regimen was similar to the childhood vaccines given alone. Nirsevimab can be given concomitantly with childhood vaccines.</p><p>&nbsp;</p><p>Nirsevimab should not be mixed with any vaccine in the same syringe or vial (see section 6.2). When administered concomitantly with injectable vaccines, they should be given with separate syringes and at different injection sites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequent adverse reaction was rash (0.7%) occurring within 14 days post dose. The majority of cases were mild to moderate in intensity. Additionally, pyrexia and injection site reactions were reported at a rate of 0.6% and 0.4% within 7 days post dose, respectively. Injection site reactions were non-serious.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table 1 presents the adverse reactions reported in 1 955 term and preterm infants (GA &ge;29 weeks) who received nirsevimab in clinical trials.</p><p>&nbsp;</p><p>Adverse reactions reported from controlled clinical trials are classified by MedDRA System Organ Class (SOC). Within each SOC, preferred terms are arranged by decreasing frequency and then by decreasing seriousness. Frequencies of occurrence of adverse reactions are defined as: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1 000 to &lt;1/100); rare (&ge;1/10 000 to &lt;1/1 000); very rare (&lt;1/10 000) and not known (cannot be estimated from available data).</p><p>&nbsp;</p><p>Table 1: Adverse reactions</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA SOC</strong></p></td><td style="vertical-align:top"><p><strong>MedDRA Preferred Term</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash<sup>a</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Injection site reaction<sup>b</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr></tbody></table><p><sup>a</sup> Rash was defined by the following grouped preferred terms: rash, rash maculo-papular, rash macular.</p><p><sup>b</sup> Injection site reaction was defined by the following grouped preferred terms: injection site reaction, injection site pain, injection site induration, injection site oedema, injection site swelling.</p><p>&nbsp;</p><p><u>Infants at higher risk for severe RSV disease</u></p><p>&nbsp;</p><p>Safety was also evaluated in MEDLEY in 918 infants at higher risk for severe RSV disease, including 196 extremely preterm infants (GA &lt;29 weeks) and 306 infants with chronic lung disease of prematurity, or haemodynamically significant congenital heart disease entering their first RSV season, who received nirsevimab (614) or palivizumab (304). The safety profile was comparable to the palivizumab comparator and consistent with the safety profile in term and preterm infants</p><p>GA &ge;29 weeks (D5290C00003 and MELODY).</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>As with all therapeutic proteins, there is potential for immunogenicity. <u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p>&nbsp;</p><p>To reports any side effect(s):</p><p><strong>Saudi Arabia:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p><strong>Sanofi Pharmacovigilance:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KSA_Pharmacovigilance@sanofi.com</p><p><strong>For any other medical inquiry: </strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; KSA.Medicalenquiry@sanofi.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment for an overdose with nirsevimab. In the event of an overdose, the individual should be monitored for the occurrence of adverse reactions and provided with symptomatic treatment as appropriate.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immune sera and immunoglobulins, antiviral monoclonal antibodies, ATC code: J06BD08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Nirsevimab is a recombinant neutralising human IgG1ĸ long-acting monoclonal antibody to the prefusion conformation of the RSV F protein which has been modified with a triple amino acid substitution (YTE) in the Fc region to extend serum half-life. Nirsevimab binds to a highly conserved epitope in antigenic site &Oslash; on the prefusion protein with dissociation constants KD = 0.12 nM and</p><p>KD = 1.22 nM for RSV subtype A and B strains, respectively. Nirsevimab inhibits the essential membrane fusion step in the viral entry process, neutralising the virus and blocking cell-to-cell fusion.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em><u>Antiviral activity</u></em></p><p><em>&nbsp;</em></p><p>The cell culture neutralisation activity of nirsevimab against RSV was measured in a dose-response model using cultured Hep-2 cells. Nirsevimab neutralised RSV A and RSV B isolates with median EC50 values of 3.2 ng/mL (range 0.48 to 15 ng/mL) and 2.9 ng/mL (range 0.3 to 59.7 ng/mL), respectively. The clinical RSV isolates (70 RSV A and 49 RSV B) were collected between 2003 and 2017 from subjects across the United States, Australia, Netherlands, Italy, China and Israel and encoded the most common RSV F sequence polymorphisms found among circulating strains.</p><p>&nbsp;</p><p>Nirsevimab demonstrated <em>in vitro </em>binding to immobilised human Fc&gamma;Rs (Fc&gamma;RI, Fc&gamma;RIIA, Fc&gamma;RIIB, and Fc&gamma;RIII) and equivalent neutralising activity compared to parental monoclonal antibodies, IG7</p><p>and IG7-TM (Fc region modified to reduce FcR binding and effector function). In a cotton rat model of RSV infection, IG7 and IG7-TM exhibited comparable dose-dependent reduction in RSV replication in the lungs and nasal turbinates, strongly suggesting that protection from RSV infection is dependent on nirsevimab neutralisation activity rather than Fc-mediated effector function.</p><p>&nbsp;</p><p><em><u>Antiviral resistance</u></em></p><p><em>&nbsp;</em></p><p><em>In cell culture</em></p><p><em>&nbsp;</em></p><p>Escape variants were selected following three passages in cell culture of RSV A2 and B9320 strains in the presence of nirsevimab. Recombinant RSV A variants that showed reduced susceptibility to nirsevimab included those with identified substitutions N67I+N208Y (103-fold). Recombinant RSV B variants that showed reduced susceptibility to nirsevimab included those with identified substitutions N208D (&gt;90,000-fold), N208S (&gt;24,000-fold), K68N+N201S (&gt;13,000-fold), or K68N+N208S</p><p>(&gt;90,000-fold). All resistance-associated substitutions identified among neutralisation escape variants were located in the nirsevimab binding site (amino acids 62-69 and 196-212) and were shown to reduce binding affinity to RSV F protein.</p><p>&nbsp;</p><p><em>In clinical trials</em></p><p><em>&nbsp;</em></p><p>In MELODY and MEDLEY, no subject with medically attended RSV lower respiratory tract infection (MA RSV LRTI) had an RSV isolate containing nirsevimab resistance-associated substitutions in any treatment group.</p><p>&nbsp;</p><p>In D5290C00003 (subjects who received a single dose of 50 mg nirsevimab irrespective of weight at time of dosing), 2 of 25 subjects in the nirsevimab group with MA RSV LRTI had an RSV isolate containing nirsevimab resistance-associated substitutions (RSV A: 0 of 11 subjects and RSV B: 2 of 14 subjects). No subjects in the placebo group had an RSV isolate containing nirsevimab</p><p>resistance-associated substitution. Recombinant RSV B variants harbouring the identified I64T+K68E+I206M+Q209R (&gt;447.1-fold) or N208S (&gt;386.6-fold) F protein sequence variations in the nirsevimab binding site conferred reduced susceptibility to nirsevimab neutralisation.</p><p>&nbsp;</p><p>Nirsevimab retained activity against recombinant RSV harbouring palivizumab resistance-associated substitutions identified in molecular epidemiology studies and in neutralisation escape variants of palivizumab. It is possible that variants resistant to nirsevimab could have cross-resistance to other monoclonal antibodies targeting the F protein of RSV.</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p>&nbsp;</p><p>The efficacy and safety of nirsevimab were evaluated in two randomised, double-blind, placebo controlled multicentre trials (D5290C00003 [Phase IIb] and MELODY [Phase III]) for the prevention of RSV LRTI in term and preterm infants (GA &ge;29 weeks) entering their first RSV season. Safety and pharmacokinetics of nirsevimab were also evaluated in a randomised, double-blind,</p><p>palivizumab-controlled multicentre trial (MEDLEY [Phase II/III]) in infants GA &lt;35 weeks at higher risk for severe RSV disease, including extremely preterm infants (GA &lt;29 weeks) and infants with chronic lung disease of prematurity, or haemodynamically significant congenital heart disease, entering their first RSV season.</p><p>&nbsp;</p><p><em><u>Efficacy against MA RSV LRTI, MA RSV LRTI hospitalisation, and very severe MA RSV LRTI in term</u> <u>and preterm infants (D5290C00003 and MELODY)</u></em></p><p><em>&nbsp;</em></p><p>D5290C00003 randomised a total of 1 453 very and moderately preterm infants (GA &ge;29 to</p><p>&lt;35 weeks) entering their first RSV season (2:1) to receive a single intramuscular dose of 50 mg nirsevimab or placebo. At randomisation, 20.3% were GA &ge;29 to &lt;32 weeks; 79.7% were GA &ge;32 to</p><p>&lt;35 weeks; 52.4% were male; 72.2% were White; 17.6% were of African origin; 1.0% were Asian;</p><p>59.5% weighed &lt;5 kg (11.6% &lt;2.5 kg); 17.3% of infants were &le;1.0 month of age, 35.9% were &gt;1.0 to</p><p>&le;3.0 months, 32.6% were &gt;3.0 to &le;6.0 months, and 14.2% were &gt;6.0 months.</p><p>&nbsp;</p><p>MELODY randomised a total of 1 490 term and late preterm infants (GA &ge;35 weeks) entering their first RSV season (2:1) to receive a single intramuscular dose of nirsevimab (50 mg nirsevimab if</p><p>&lt;5 kg weight or 100 mg nirsevimab if &ge;5 kg weight at the time of dosing) or placebo. At randomisation, 14.0% were GA &ge;35 to &lt;37 weeks; 86.0% were GA &ge;37 weeks; 51.6% were male; 53.5% were White; 28.4% were of African origin; 3.6% were Asian; 40.0% weighed &lt;5 kg (1.7%</p><p>&lt;2.5 kg); 24.5% of infants were &le;1.0 month of age, 33.4% were &gt;1.0 to &le;3.0 months, 32.1% were</p><p>&gt;3.0 to &le;6.0 months, and 10.0% were &gt;6.0 months.</p><p>&nbsp;</p><p>The trials excluded infants with a history of chronic lung disease/bronchopulmonary dysplasia or congenital heart disease (except for infants with uncomplicated congenital heart disease).</p><p>Demographic and baseline characteristics were comparable between the nirsevimab and placebo group in both trials.</p><p>&nbsp;</p><p>The primary endpoint for D5290C00003 and MELODY was the incidence of medically attended lower respiratory tract infection (inclusive of hospitalisation) caused by RT-PCR-confirmed RSV (MA RSV LRTI), characterised predominantly as bronchiolitis or pneumonia, through 150 days after dosing. Signs of LRTI were defined by having one of the following findings at physical examination indicating lower respiratory tract involvement (e.g., rhonchi, rales, crackles, or wheeze); and at least one sign of clinical severity (increased respiratory rate, hypoxemia, acute hypoxic or ventilatory failure, new onset apnoea, nasal flaring, retractions, grunting, or dehydration due to respiratory distress). The secondary endpoint was the incidence of hospitalisation in infants with MA RSV LRTI. RSV hospitalisation was defined as hospitalisation for LRTI with a positive RSV test, or worsening of respiratory status and positive RSV test in an already hospitalised patient. Very severe MA RSV LRTI was also evaluated, defined as MA RSV LRTI with hospitalisation and requirement for supplemental oxygen or intravenous fluids.</p><p>&nbsp;</p><p>The efficacy of nirsevimab in term and preterm infants (GA &ge;29 weeks) entering their first RSV season against MA RSV LRTI, MA RSV LRTI with hospitalisation and very severe MA RSV LRTI are shown in Table 2.</p><p>Table 2: Efficacy in term and preterm infants against MA RSV LRTI, MA RSV LRTI with hospitalisation and very severe MA RSV LRTI through 150 days post dose, D5290C00003 and MELODY</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Group</strong></p></td><td style="vertical-align:top"><p><strong>Treatment</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>Incidence</strong></p><p><strong>% (n)</strong></p></td><td style="vertical-align:top"><p><strong>Efficacy</strong>a <strong>(95% CI)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Efficacy in infants against MA RSV LRTI through 150 days post dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Very and moderately preterm GA &ge;29 to &lt;35 weeks (D5290C00003)<sup>b</sup></p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>969</p></td><td style="vertical-align:top"><p>2.6 (25)</p></td><td rowspan="2" style="vertical-align:top"><p>70.1% (52.3, 81.2)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>484</p></td><td style="vertical-align:top"><p>9.5 (46)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Term and late preterm GA &ge;35 weeks (MELODY)</p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>994</p></td><td style="vertical-align:top"><p>1.2 (12)</p></td><td rowspan="2" style="vertical-align:top"><p>74.5% (49.6, 87.1)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>496</p></td><td style="vertical-align:top"><p>5.0 (25)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Efficacy in infants against MA RSV LRTI with hospitalisation through 150 days post dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Very and moderately preterm GA &ge;29 to &lt;35 weeks (D5290C00003)<sup>b</sup></p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>969</p></td><td style="vertical-align:top"><p>0.8 (8)</p></td><td rowspan="2" style="vertical-align:top"><p>78.4% (51.9, 90.3)<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>484</p></td><td style="vertical-align:top"><p>4.1 (20)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Term and late preterm GA &ge;35 weeks (MELODY)</p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>994</p></td><td style="vertical-align:top"><p>0.6 (6)</p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>62.1% (-8.6, 86.8)</p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>496</p></td><td style="vertical-align:top"><p>1.6 (8)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Efficacy in infants against very severe MA RSV LRTI through 150 days post dose</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Very and moderately preterm GA &ge;29 to &lt;35 weeks (D5290C00003)<sup>b</sup></p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>969</p></td><td style="vertical-align:top"><p>0.4 (4)</p></td><td rowspan="2" style="vertical-align:top"><p>87.5% (62.9, 95.8)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>484</p></td><td style="vertical-align:top"><p>3.3 (16)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Term and late preterm GA &ge;35 weeks (MELODY)</p></td><td style="vertical-align:top"><p>Nirsevimab</p></td><td style="vertical-align:top"><p>994</p></td><td style="vertical-align:top"><p>0.5 (5)</p></td><td rowspan="2" style="vertical-align:top"><p>64.2% (-12.1, 88.6)<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>496</p></td><td style="vertical-align:top"><p>1.4 (7)</p></td></tr></tbody></table><p><sup>a</sup> Based on relative risk reduction versus placebo.</p><p><sup>b</sup> All subjects who received 50 mg irrespective of weight at the time of dosing.</p><p><sup>c</sup> Prespecified multiplicity controlled; p-value =&lt;0.001.</p><p><sup>d</sup> Not multiplicity controlled.</p><p>Subgroup analyses of the primary efficacy endpoint by gestational age, gender, race and region showed results were consistent with the overall population.</p><p>&nbsp;</p><p>The severity of breakthrough cases of subjects hospitalised for MA RSV LRTI was assessed. The percentage of subjects who required supplementary oxygen was 44.4% (4/9) vs. 81.0% (17/21), subjects who required continuous positive airway pressure [CPAP]/high flow nasal cannula [HFNC] was 11.1% (1/9) vs. 23.8% (5/21), and 0% (0/9) vs. 28.6% (6/21) subjects were admitted to intensive care unit, for nirsevimab vs. placebo, respectively.</p><p>&nbsp;</p><p><em><u>Efficacy against MA RSV LRTI in infants at higher risk for severe RSV disease (MEDLEY)</u></em></p><p><em>&nbsp;</em></p><p>MEDLEY randomised a total of 925 infants at higher risk for severe RSV disease including infants with chronic lung disease or congenital heart disease and preterm infants GA &lt;35 weeks, entering their first RSV season. Infants received a single intramuscular dose (2:1) of nirsevimab (50 mg nirsevimab if &lt;5 kg weight or 100 mg nirsevimab if &ge;5 kg weight at the time of dosing) or 5 monthly intramuscular doses of 15 mg/kg palivizumab. At randomisation, 21.6% were GA &lt;29 weeks; 21.5% were GA&ge;29 to &lt;32 weeks; 41.9% were GA &ge;32 to &lt;35 weeks; 14.9% were GA &ge;35 weeks. Of these infants 23.6% had chronic lung disease; 11.2% had congenital heart disease; 53.5% were male; 79.2% were White; 9.5% were of African origin; 5.4% were Asian; 56.5% weighed &lt;5 kg (6.4% were</p><p>&lt;2.5 kg); 11.4% of infants were &le;1.0 month of age, 33.8% were &gt;1.0 to &le;3.0 months 33.6% were</p><p>&gt;3.0 months to &le;6.0 months, and 21.2% were &gt;6.0 months.</p><p>&nbsp;</p><p>The efficacy of nirsevimab in infants at higher risk for severe RSV disease is extrapolated from the efficacy of nirsevimab in D5290C00003 and MELODY based on pharmacokinetic exposure (see</p><p>section 5.2). In MEDLEY, the incidence of MA RSV LRTI through 150 days post dose was 0.6% (4/616) in the nirsevimab group and 1.0% (3/309) in the palivizumab group.</p><p><em><u>Duration of protection</u></em></p><p><em>&nbsp;</em>Based on clinical and pharmacokinetic data, the duration of protection afforded by nirsevimab is at least 5 months.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic properties of nirsevimab are based on data from individual studies and population pharmacokinetic analyses. The pharmacokinetics of nirsevimab were dose-proportional in infants and adults following administration of clinically relevant intramuscular doses over a dose range of 25 mg to 300 mg.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following intramuscular administration, the maximum concentration was reached within 6 days (range 1 to 28 days) and the estimated absolute bioavailability was 85%.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The estimated central and peripheral volume of distribution of nirsevimab were 249 mL and 241 mL, respectively, for an infant weighing 5 kg. The volume of distribution increases with increasing body weight.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Nirsevimab is a human IgG1&kappa; monoclonal antibody that is degraded by proteolytic enzymes widely distributed in the body and not metabolised by hepatic enzymes.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>As a typical monoclonal antibody, nirsevimab is eliminated by intracellular catabolism and there is no evidence of target-mediated clearance at the doses tested clinically.</p><p>&nbsp;</p><p>The estimated clearance of nirsevimab was 3.38 mL/day for an infant weighing 5 kg and the terminal half-life was approximately 69 days. Nirsevimab clearance increases with increasing body weight.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Race</u></em></p><p><em>&nbsp;</em></p><p>There was no clinically relevant effect of race.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p><em>&nbsp;</em></p><p>No clinical studies have been conducted to investigate the effect of renal impairment. As a typical IgG monoclonal antibody, nirsevimab is not cleared renally due to its large molecular weight, change in renal function is not expected to influence nirsevimab clearance.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p><em>&nbsp;</em></p><p>No clinical studies have been conducted to investigate the effect of hepatic impairment. As IgG monoclonal antibodies are not primarily cleared via the hepatic pathway, change in hepatic function is not expected to influence nirsevimab clearance.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Infants at higher risk for severe RSV disease</u></em></p><p><em>&nbsp;</em></p><p>There was no significant influence of chronic lung disease or congenital heart disease on the pharmacokinetics of nirsevimab.</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship(s)</u></p><p>&nbsp;</p><p>In D5290C00003 and MELODY a positive correlation was observed between a serum AUC (based on clearance at baseline) above 12.8 mg*day/mL and a lower incidence of MA RSV LRTI. The recommended dosing regimen consisting of a 50 mg or 100 mg intramuscular dose for infants in their first RSV season was selected on the basis of these results.</p><p>&nbsp;</p><p>In MEDLEY, &gt;80% of infants at higher risk for severe RSV disease, including infants born extremely preterm (GA &lt;29 weeks) and infants with chronic lung disease or congenital heart disease, achieved nirsevimab exposures associated with RSV protection (serum AUC above 12.8 mg*day/mL) following a single dose (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on studies of safety pharmacology, repeated dose toxicity and tissue cross-reactivity studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L-histidine</p><p>L-histidine hydrochloride L-arginine hydrochloride Sucrose</p><p>Polysorbate 80 Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                15 months
Beyfortus may be kept at room temperature (20°C - 25°C) when protected from light for a maximum of 8 hours. After this time, the syringe must be discarded.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C - 8&deg;C). Do not freeze.</p><p>Do not shake or expose to direct heat.</p><p>&nbsp;</p><p>Keep the pre-filled syringe in the outer carton in order to protect from light. For storage conditions of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Siliconised Luer lock Type I glass pre-filled syringe with a FluroTec-coated plunger stopper. Each pre-filled syringe contains 0.5 mL or 1 mL solution.</p><p>Pack sizes:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe packaged with two separate needles of different sizes.</p><p>OR</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1 pre-filled syringe without needles.</p><p>&nbsp;</p><p>&nbsp;</p><p>Not all pack sizes may be marketed<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should be administered by a trained healthcare professional using aseptic techniques to ensure sterility.</p><p>Visually inspect the medicinal product for particulate matter and discolouration prior to administration. The medicinal product is a clear to opalescent, colourless to yellow solution. Do not inject if the liquid is cloudy, discoloured, or it contains large particles or foreign particulate matter.</p><p>Do not use if the pre-filled syringe has been dropped or damaged or the security seal on the carton has been broken.</p><p><u>Disposal</u></p><p>Each pre-filled syringe is for single-use only. Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sanofi Winthrop Industrie
82 avenue Raspail
94250 Gentilly
France

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Date of first authorisation: To be added upon SFDA authorization approval.
Date of last revision: 15-Nov-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>